Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ongoing clinical studies aimed at expanding its use beyond acute pain management.

This drug may reduce the risk of addiction to pain medications by decreasing reliance on opioids to reduce pain.

The FDA approves a new non-opioid pain pill, Journavx, to treat acute pain in adults. It's a first-generation non-addictive ...

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

About JOURNAVX™ (suzetrigine) JOURNAVX (suzetrigine) is a first-in-class, oral, non-opioid, highly selective pain signal inhibitor that is selective for NaV1.8 relative to other NaV channels.

Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX ...

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) has recently achieved a significant milestone with the FDA's approval of JOURNAVX(suzetrigine), a novel non-opioid pain medication. This approval marks ...

Journavx (suzetrigine) is a new nonopioid medication manufactured by Vertex Pharmaceuticals to help treat and manage moderate to severe acute pain. While opioids work by attaching to special ...

The stock’s price increase is mainly because the company gained approval for two new products, its novel non-opioid pain medicine Journavx (suzetrigine) and its fifth cystic franchise (CF ...